Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Cancer

Volumn 121, Issue 7, 2015, Pages 997-1007

  Field, Kathryn M ^a   Jordan, Justin T ^b   Wen, Patrick Y ^b   Rosenthal, Mark A ^a   Reardon, David A ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

angiogenesis; bevacizumab; glioblastoma; malignant glioma; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CETUXIMAB; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GELATINASE A; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; PANOBINOSTAT; PLACEBO; RO 5323441; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COGNITION; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; GENE; GENE SIGNATURE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; VENOUS THROMBOEMBOLISM; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC);

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; QUALITY OF LIFE;

EID: 84925372706     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28935     Document Type: Review

References (88)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
3. Nieder C, Grosu AL, Molls M,. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000; 26: 397-409.
4. Arrillaga-Romany I, Reardon DA, Wen PY,. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014; 23: 199-210.
5. Plate KH, Breier G, Weich HA, Risau W,. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359: 845-848.
6. Shih AH, Holland EC,. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006; 232: 139-147.
7. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13: 206-220.
8. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun. 2002; 291: 908-914.
9. Reardon DA, Turner S, Peters KB, et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011; 9: 414-427.
10. Das S, Marsden PA,. Angiogenesis in glioblastoma. N Engl J Med. 2013; 369: 1561-1563.
11. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468: 829-833.
12. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468: 824-828.
13. Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A. 2011; 108: 4274-4280.
14. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
15. Jain RK,. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
16. Le Serve AW, Hellmann K,. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. BMJ. 1972; 1: 597-601.
17. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6: 553-563.
18. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
19. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA,. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol. 2009; 11: 142-150.
20. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 841-844.
21. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60: 5565-5570.
22. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000; 2: 306-314.
23. Mathieu V, De Neve N, Le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008; 10: 1383-1392.
24. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19: 843-850.
25. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001; 19: 851-856.
26. Stark-Vance V,. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol. 2005; 7: 91. Abstract 369.
27. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-1259.
28. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729.
29. Ballman KV, Buckner JC, Brown PD, et al. The relationship between 6-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007; 9: 29-38.
30. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008; 10: 162-170.
31. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
32. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
33. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740-745.
34. Cohen MH, Shen YL, Keegan P, Pazdur R,. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14: 1131-1138.
35. Balana C, Etxaniz O, Buges C, Martinez A,. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin Transl Oncol. 2011; 13: 209-210.
36. Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS,. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther. 2013; 6: 371-389.
37. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010; 116: 5297-5305.
38. Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012; 118: 1302-1312.
39. Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a North Central Cancer Treatment Group trial. Clin Cancer Res. 2013; 19: 4816-4823.
40. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010; 12: 508-516.
41. Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS,. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013; 33: 1657-1660.
42. Moller S, Grunnet K, Hansen S, et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012; 51: 797-804.
43. Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012; 107: 155-164.
44. Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011; 117: 5351-5358.
45. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009; 101: 1986-1994.
46. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010; 12: 1300-1310.
47. Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol. 2014; 116: 533-541.
48. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008; 109: 268-272.
49. Arakawa Y, Mizowaki T, Murata D, et al. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. Neurol Med Chir (Tokyo). 2013; 53: 779-785.
50. Bokstein F, Shpigel S, Blumenthal DT,. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008; 112: 2267-2273.
51. Cecchi M, Vaiani M, Ceroti M, Banfi R,. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma. Int J Clin Pharm. 2013; 35: 483-487.
52. Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci. 2010; 17: 970-974.
53. Kang TY, Jin T, Elinzano H, Peereboom D,. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008; 89: 113-118.
54. Mrugala MM, Crew LK, Fink JR, Spence AM,. Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett. 2012; 4: 1082-1086.
55. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009; 72: 1217-1222.
56. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-787.
57. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF,. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66: 1258-1260.
58. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009; 91: 329-336.
59. Herrlinger U, Schaefer N, Steinbach P, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial [abstract]. J Clin Oncol. 2013;Vol(suppl). Abstract LBA2000.
60. Taal W, Walenkamp W, Beerepoot L, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2001.
61. Chinot O, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709-722.
62. Gilbert M, Dignam J, Armstrong T, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 699-708.
63. Raizer JJ, Giglio P, Hu JL, et al. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2019.
64. Reyes-Botero G, Honnorat J, Chinot OL, et al. Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial. [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2020.
65. Nicholas MK, Lukas RV, Amidei C, et al. Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly diagnosed adult glioblastoma patients [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2076.
66. Field KM, Simes J, Wheeler H, et al. A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2017.
67. Sepulved JM, Belda-Iniesta C, Gil M, et al. Bevacizumab in combination with TMZ in patients with recurrent GBM: Final OS and PFS analysis [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2087.
68. Lee EQ, Reardon DA, Schiff D, et al. Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2020.
69. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-1972.
70. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013; 31: 3212-3218.
71. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010; 28: 1168-1174.
72. Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2005.
73. Armstrong T, Won M, Wefel J, et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2003.
74. Wefel J, Pugh S, Armstrong T, et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract]. J Clin Oncol. 2013; 31 (suppl): Abstract 2004.
75. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF,. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013; 13: 347.
76. Tanne JH,. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ. 2011; 343: d7684.
77. Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014; 16: 696-706.
78. Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol. 2010; 12: 164-172.
79. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009; 9: 444.
80. Nishikawa R, Saran F, Mason W, et al. Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T), for newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2023.
81. Sulman E, Won M, Blumenthal D, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract LBA2010.
82. Di Stefano A, Lombardi G, Perez-Larray J, et al. Association of VEGFA SNP rs2010963 with prognosis and prediction of vascular toxicity of bevacizumab in recurrent glioblastomas [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2028.
83. Huse J, Beak K, Zhang J, et al. Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2057.
84. Tabouret E, Boudouresque F, Barrie M, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014; 16: 392-399.
85. Tabouret E, Boudouresque F, Perez-Larraya J, et al. Association of matrix metalloproteinase 2 (MMP2) baseline plasma level to objective response (OR), progression free survival (PFS), and overall survival (OS) and changes under treatment in patients treated with bevacizumab (Bev) for recurrent high-grade glioma (HGG) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2024.
86. Ellingson B, Kim HT, Woodworth D, et al. Contrast-enhanced T1-weighted subtraction maps for response assessment in recurrent glioblastoma treated with bevacizumab [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2055.
87. Eoli M, Di Stefano A, Aquino D, et al. Tumor perfusion during bevacizumab and irinotecan in recurrent glioblastoma: a multimodal approach [abstract]. J Clin Oncol. 2013; 31 (suppl): Abstract 2074.
88. Huang R, Rahman R, Hamdan A, et al. Recurrent glioblastoma: stratification of patient survival using tumor volume before and after antiangiogenic treatment [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 2075.